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of the time to symptom progression (TSP), time to deterioration (TTD) in trial 
outcome index (TOI), and time to deterioration (TTD) in QoL. An exploratory analy-
sis based on the time to analgesia and appearance of key symptoms (pain, cough, and 
dyspnea) was also performed. RESULTS: FACT-L completion rates were above 90% 
at almost all study visits. At baseline, QoL measures were similar between the two 
treatment groups. Maintenance therapy with erlotinib did not negatively impact on 
QoL, compared with placebo, as illustrated by comparable TSP (HR = 0.91 [0.74–
1.12], n = 785), TTD in TOI (HR = 1.06 [0.87–1.31], n = 781), or TTD in QoL (HR 
= 0.96 [0.79–1.16], n = 776). Exploratory analysis of NSCLC-related symptomatology 
showed that time to pain and time to analgesic use were signiﬁ cantly delayed in 
patients receiving erlotinib compared with placebo (HR = 0.61 [0.42–0.88]; P = 
0.0080 and HR = 0.66 [0.46–0.94]; P = 0.0199, respectively). There was also a 
nonsigniﬁ cant trend toward delayed time to cough and time to dyspnea (HR = 0.77 
[0.49–1.21] and HR = 0.75 [0.48–1.17], respectively). CONCLUSIONS: Erlotinib 
maintenance therapy signiﬁ cantly extends progression-free survival, without compro-
mising patient QoL and with some improvement in symptoms.
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OBJECTIVES: The aim of the EPICLIN-Lung study is to provide information on the 
impact and overall resource burden of the diverse strategies used across Europe for 
the management of NSCLC. Quality of life (QoL) and health state (HS) were deter-
mined by patient-reported outcome (PRO) questionnaires. METHODS: The EPI-
CLIN-Lung study (NCT00831909) is a noninterventional prospective cohort study 
conducted in Belgium, France, Germany, Greece, Italy, Portugal, Spain, and Turkey. 
Patients with conﬁ rmed NSCLC attending a participating clinical department for the 
ﬁ rst time between January and March 2009 were included. QoL and HS were assessed 
at baseline (Visit 1) by the responses to the PRO questionnaires FACT-L (Functional 
Assessment of Cancer Therapy-Lung) and EQ5D (EuroQoL-5D), respectively. 
RESULTS: Patients (N = 1500) received the questionnaires at Visit 1. QoL data werer 
available for 1500 patients and overall FACT-L mean score (±SD) was 93.4 (21.3). 
HS data were available for a total of 1402 patients, overall EQ5D mean score (±SD) 
was 63.3 (19.9). Mean scores (±SD) split by disease stage IIIb (FACT-L, n = 276; 
EQ5D, n = 258) and IV (FACT-L, n = 694; EQ5D, n = 653) were 93.5 (20.1) and 
91.3 (21.6) for FACT-L, respectively, and 64.2 (18.7) and 61.0 (20.5) for EQ5D, 
respectively. Mean scores (±SD) split by age <80 (FACT-L, n = 1,428; EQ5D, n = 
1,348) and age ≥80 (FACT-L, n = 61; EQ5D, n = 54) were 93.5 (21.4) and 92.9 (18.7) 
for FACT-L, respectively, and 63.5 (19.9) and 60.4 (19.9) for EQ5D, respectively. 
Mean scores (±SD) for patients with performance status 0, 1, 2, 3, and 4 were 100.9 
(18.7), 94.3 (21.3), 84.9 (20.9), 84.4 (21.0), and 85.0 (20.4), respectively, for FACT-L 
and 71.6 (17.6), 63.4 (19.3), 57.3 (17.9), 54.5 (21.3), and 55.0 (15.3), respectively, 
for EQ5D. CONCLUSIONS: This study provides a robust utility that could be used 
in the ﬁ nal analysis to assess the QoL and HS of NSCLC patients across Europe. More 
mature results and analysis will be provided at the meeting.
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OBJECTIVES: The Translation Unit of the EORTC is responsible for coordinating 
new translations of HRQOL tools. According to the Translation Procedure described 
in the Translation Manual, one step is pilot-testing, involving 10 to 15 patients who 
comment on the new translation. This abstract’s aim is to review the difﬁ culties in 
translating sensitive issues (body image, death, etc.). METHODS: During the pilot 
testing, patients are interviewed about the translation, ﬁ lling in answer sheets. a report 
with their comments is reviewed by the Translation Unit. All questions with comments 
from at least two patients must be analyzed. The three possible reactions are to accept 
new translations suggested by the patients, to reword the English item, and provide a 
new translation or to provide no change (e.g., because the only solution would be to 
delete the item). Fifteen reports of QLQ-MY20 translations were analyzed. RESULTS: 
In the most recent 15 translations of QLQ-MY20, pilot-tested on 85 patients in 16 
countries, there were ﬁ ve language versions that caused no problem and 10 that 
received comments about offensiveness or disturbing nature of questions about body 
image and future perspectives (especially in countries such as China, Hong Kong, 
Thailand, Lebanon, where body image and death are taboos). All together, there were 
82 comments about four items (giving 20 translated questions causing difﬁ culties) 
which required thorough analysis and discussion. Results of the analysis included 
changing six translations (rewording, accepting patients’ suggestions), refusing ﬁ ve 
suggestions (they deviated from the source too much) and leaving nine translations 
without changes (since there were no suggestions and rewording was impossible). 
CONCLUSIONS: Scales concerning sexual functions, body image, and future perspec-
tives tend to raise concerns, especially in Asian and Arabic countries. However, such 
issues are resolved in the pilot-testing stage of the Translation Procedure through 
discussions, and linguistic and medical analyses of both source and target items.
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OBJECTIVES: The objective was to assess the improvement in quality-of-life out-
comes with interferon-alpha compared to sunitinib in treatment-naïve advanced/meta-
static renal cell carcinoma in patients. METHODS: Studies were retrieved from 
Embase, Pubmed, Cochrane, and DARE databases using relevant search strategies. 
Randomized controlled trials which compared IFN with sunitinib were included 
according to prespeciﬁ ed inclusion/exclusion criteria. The quality-of-life (QoL) data 
presented in the studies was independently extracted by two reviewers and differences 
were reconciled by a third reviewer. All studies were critically appraised and data was 
analyzed using STATA version 9.2. RESULTS: Of the 463 studies identiﬁ ed, three 
studies met the inclusion criteria. FKSI-DRS index was reported in one study with 
baseline and endpoint values as 29.55 and 27.4 with IFN-α and 29.74 and 29.4 with 
sunitinib (P < 0.0001). FKSI-15 index was reported in two studies with mean baseline 
and endpoint values as 46.1 and 42.1 with IFN-α and 46.45 and 45.3 with sunitinib 
(P < 0.0001). FACT-G score was reported in one study. The baseline FACT-G score 
was 81.25 with IFN-α and 82.3 with sunitinib. The endpoint FACT-G score was 76.8 
with IFN-α and 82.3 with sunitinib (P < 0.0001). EQ-5D score was reported in two 
of the included studies and was reported to be 0.76 and 0.73 as mean baseline and 
endpoint score for IFN-α group and 0.76 and 0.76 for sunitinib group. EQ-VAS score 
was reported in one study and was 71.43 and 68.7 as baseline and end point for IFN-α 
group and 73.8 and 73.4 for sunitinib group. The overall survival rate and response 
rate was better with sunitinib as compared to IFN-α. CONCLUSIONS: Improvement 
in quality-of-life outcomes was better in patients treated with IFN-α as compared to 
sunitinib at the end point. IFN-α continues to remain a treatment of choice despite of 
limited efﬁ cacy and tolerability.
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OBJECTIVES: The aim of this study was to compare the impact of two common 
treatment of breast cancer on quality of life in women with early stage of breast cancer. 
METHODS: A double-blind cohort study was done in 100 breast cancer patients with 
node positive that used 5-ﬂ uorouracil, doxorubicin, cyclophosphamide (FAC) or 
docetaxel, doxorubicin, and cyclophosphamide (TAC) regimen as adjuvant therapies. 
Patients were followed for 4 months since end of chemotherapy. Health-related quality 
of life was assessed using questionnaire from European organization for research and 
treatment of cancer (EORTC) QLQ-C30. Independent t-test analysis was used at the 
signiﬁ cant level of 0.05 for analyzing the results. RESULTS: The mean of age was 
49.2911.59 and 46.718.23 years old in TAC and FAC groups, respectively. In the end 
of chemotherapy, QoL score were 64 and 68 in TAC and FAC groups, respectively 
(P < 0.005). After 4 months, patients in TAC and FAC groups experienced 11.45 and 
7.14 units improvement in QoL scores, respectively (P = 0.02). CONCLUSIONS: 
Although, TAC had a more negative impact on QoL during chemotherapy, it created 
a higher improvement than FAC during 4 months since end of treatment. These effects 
on quality of life should be considered in making decision for providing and ﬁ nancing 
cancer treatments in Iran.
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OBJECTIVES: Although improved lung cancer survival is likely to result in increased 
lung cancer survivors, little was known about work situation among lung cancer 
survivors. The purpose of this study was to investigate employment status and work-
related difﬁ culties of lung cancer survivors compared with the general population. 
METHODS: We enrolled 917 lung cancer survivors from two hospitals 12 months 
after lung cancer surgery and 1000 volunteers from the general population. Multivari-
ate logistic regression was used to identify the factors associated with work situation. 
RESULTS: Employment decreased from 69.6% to 38.7% after cancer treatment. The 
proportion of lung cancer survivors who remained working was signiﬁ cantly smaller 
relative to that of the general population (63.5%) (adjusted odds ratio [aOR] = 2.59; 
95% conﬁ dence interval [CI]: 1.91 to 3.51). In subgroup analyses, female survivors 
over 65 years had unemployed after treatment (aOR = 89.24; 95%CI = 10.52 to 
756.91) than at the diagnosis of cancer. Among cancer survivor who remained 
employed after treatment (n = 284), 71.8% found no meaning of working and 15% 
experienced decrease wages. CONCLUSIONS: This is the ﬁ rst study with the largest 
number of patients investigating employment situation among lung cancer survivors 
reported poorer employment status than the general population. Among cancer sur-
